Literature DB >> 10579928

Multiple roles for Src in a PDGF-stimulated cell.

K A DeMali1, S L Godwin, S P Soltoff, A Kazlauskas.   

Abstract

The observation that platelet-derived growth factor (PDGF) increases the catalytic activity of Src family members (Src) suggests that they contribute to PDGF-dependent responses. The role of Src in PDGF-dependent cell cycle progression, phosphorylation of proteins, and chemotaxis has been tested by investigators using a variety of cell types and approaches, and it appears that the contribution of Src is highly variable. This idea is perhaps best illustrated by the finding that Src plays radically different roles downstream of the PDGF alpha- and beta-receptor subunits. Hence, Src is a versatile signal relay enzyme, whose contribution to a signaling cascade depends on variables such as the nature of the receptor via which the cell is activated, as well as the cell type itself. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10579928     DOI: 10.1006/excr.1999.4669

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  8 in total

1.  Divergent roles of c-Src in controlling platelet-derived growth factor-dependent signaling in fibroblasts.

Authors:  Kavita Shah; Fabien Vincent
Journal:  Mol Biol Cell       Date:  2005-08-31       Impact factor: 4.138

Review 2.  Dasatinib: a potent SRC inhibitor in clinical development for the treatment of solid tumors.

Authors:  John Araujo; Christopher Logothetis
Journal:  Cancer Treat Rev       Date:  2010-03-11       Impact factor: 12.111

3.  Distinct effectors of platelet-derived growth factor receptor-alpha signaling are required for cell survival during embryogenesis.

Authors:  Melanie Van Stry; Andrius Kazlauskas; Stuart L Schreiber; Karen Symes
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-26       Impact factor: 11.205

4.  Identification of c-Src tyrosine kinase substrates in platelet-derived growth factor receptor signaling.

Authors:  Ramars Amanchy; Jun Zhong; Rosa Hong; James H Kim; Marjan Gucek; Robert N Cole; Henrik Molina; Akhilesh Pandey
Journal:  Mol Oncol       Date:  2009-07-10       Impact factor: 6.603

Review 5.  Improving the prognosis for patients with glioblastoma: the rationale for targeting Src.

Authors:  John de Groot; Vanessa Milano
Journal:  J Neurooncol       Date:  2009-05-13       Impact factor: 4.130

6.  Activation of Src kinase in platelet-derived growth factor-B-dependent tubular regeneration after acute ischemic renal injury.

Authors:  Mikiko Takikita-Suzuki; Masakazu Haneda; Masakiyo Sasahara; M Koji Owada; Takahiko Nakagawa; Motohide Isono; Shoichi Takikita; Daisuke Koya; Kazumasa Ogasawara; Ryuichi Kikkawa
Journal:  Am J Pathol       Date:  2003-07       Impact factor: 4.307

7.  Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.

Authors:  E F Dunn; M Iida; R A Myers; D A Campbell; K A Hintz; E A Armstrong; C Li; D L Wheeler
Journal:  Oncogene       Date:  2010-10-18       Impact factor: 9.867

8.  MLLT11/AF1q boosts oncogenic STAT3 activity through Src-PDGFR tyrosine kinase signaling.

Authors:  Jino Park; Soojin Kim; Joongho Joh; Scot C Remick; Donald M Miller; Jun Yan; Zeyad Kanaan; Ju-Hsien Chao; Maxwell M Krem; Soumit K Basu; Shotaro Hagiwara; Lukas Kenner; Richard Moriggl; Kevin D Bunting; William Tse
Journal:  Oncotarget       Date:  2016-07-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.